[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"xerostomia-following-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:xerostomia-following-radiotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100636874","the-effect-of-ozone-on-salivary-flow-in-patients-with-xerostomia-and-hyposalivation-after-radiotherapy-ozonexerostomi-100636874",false,"NCT07571356","The Effect of Ozone on Salivary Flow in Patients With Xerostomia and Hyposalivation After Radiotherapy (OZONEXEROSTOMI)","The Effect of Ozone Therapy on Salivary Flow and Quality of Life in Patients With Xerostomia and Hyposalivation After Head and Neck Radiotherapy","ozonexerostomi","Inclusion Criteria:\n\n* Patients who have undergone head and neck radiotherapy\n* Patient who have developed xerostomia\n* Patient who have developed hyposalivation\n\nExclusion Criteria:\n\n* Patients with active malignant disease\n* Patients who do not agree to sign the informed consent form","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients who underwent head and neck radiotherapy and developed xerostomia and\u002For hyposalivation will be selected. The patients will be randomly assigned into two groups, defined as control and treatment.\n\nAll patients will complete the xerostomia-related quality of life questionnaires, XeQoLS (Xerostomia Quality of Life Scale) and OHIP (Oral Health Impact Profile). This qualitative assessment will be repeated 1 week after the 6th application and 1 week after the 12th application (T0, T6, and T12).\n\nThe quantitative assessment will be carried out through the collection of unstimulated and stimulated saliva at the same time points (T0, T6, and T12).\n\nPatients will undergo 12 sessions of ozone therapy, once a week, in gaseous form, at a concentration of 10 µg\u002FmL (micrograms per milliliter), applied directly into the major salivary glands.\n\nThe gas will be administered as follows:\n\n* Parotid glands: two distinct points per gland, 1 mL at each point.\n* Submandibular glands: one point per gland, 1 mL per point at 10 µg\u002FmL.\n* Sublingual glands: one point per gland, 1 mL per point at 10 µg\u002FmL. The ozone generator equipment will be supplied with medical oxygen (99.5% purity), Dental model, Philozon company.\n\nDisposable syringes will be Terumo, 10 mL, and the needle will be BD, 30\u002F13 mm.",[27],"Xerostomia Following Radiotherapy",[29,30,31,32],"xerostomia","ozone","hiposalivation","radio therapy","NOT_YET_RECRUITING","2026-05-04",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":21},"2026-07-15",{"date":41,"type":21},"2028-01-15",{"name":43,"class":44},"University of Brasilia","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100595238","laser-acupoints-stimulation-on-xerostomia-related-chemoradiotherapy-for-head-and-neck-cancer-patients-100595238","NCT07029854","Laser Acupoints Stimulation on Xerostomia Related Chemoradiotherapy for Head and Neck Cancer Patients","Inclusion Criteria:\n\n* Chemoradiation therapy\n* Carcinoma in the head and neck area (NPC)\n* Anatomically intact parotid and submandibular glands.\n* All patients will be clinically and medically stable when attending the study.\n\nExclusion Criteria:\n\n* They had a history of xerostomia;\n* They had suspected or confirmed physical closure of salivary gland.\n* ducts on either side.\n* They had known bleeding disorders.\n* They Were taking heparin or warfarin.\n* They had contraindications for the use of acupuncture at any acupoints.\n* They had history of cerebrovascular accident or spinal cord injury.\n* They had taken any drug or herbal medicine in the past 30 days that could affect salivary function.\n* They were planning to, or ended up taking such a substance during the study.\n* Any therapy that may affect treatment.","40 Years","70 Years",{"count":54,"type":21},54,[24],"The purpose of the study is to evaluate to effect of LASER acupoints stimulations on xerostomia patients during chemoradiation therapy after head and neck cancer.",[58,27],"Head and Neck Cancer","2025-06-12",{"date":61,"type":37},"2025-06-19",{"date":63,"type":21},"2025-06-18",{"date":65,"type":21},"2025-08-31",{"name":67,"class":44},"Cairo University",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":68},"100556854","phase-2-pretreatment-botulinum-toxin-in-head-and-neck-cancer-surgery-100556854","NCT06530524","Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery","Pretherapy Botulinum Toxin to Reduce Radiation-related Xerostomia in Head and Neck Cancer","Inclusion Criteria:\n\n* Newly diagnosis AJCC 8th edition Stage III\u002FIVa mucosal head and neck squamous cell carcinoma requiring definitive radiotherapy (with or without chemotherapy).\n\nExclusion Criteria:\n\n* Previous radiation to the head and neck\n* Previous treatment for head and neck cancer\n* Personal history of xerostomia\n* Hypersensitivity to onabotulinumtoxinA\n* Previous major salivary gland surgery\n* Previous exposure to radioactive iodine therapy",{"count":77,"type":21},50,[79],"PHASE2","Head and neck cancer care, including tumors of the mouth, nose, throat and voice box, often requires radiation for cure to be achieved. Despite advances in radiation, 40% to 60% of patients experience a significant dry mouth (xerostomia) following radiotherapy. Several factors are associated with severe xerostomia including older age, advanced stage disease and tumor location. Currently, no pragmatic treatment strategy exists to reduce the risk of radiation-related xerostomia in patients with head and neck cancer. The investigators propose the use of a botulinum neurotoxin injected into the at-risk salivary glands before radiation as a strategy to preserve salivary gland function during radiation treatments and reduce xerostomia.",[82,27],"Head Neck Cancer",[58,84,85,86],"Radiation induce xerostoma","botulinum toxin","salivary glands","2024-07-26",{"date":89,"type":37},"2024-07-31",{"date":91,"type":21},"2024-10-01",{"date":93,"type":21},"2027-12-01",{"name":95,"class":44},"Sir Mortimer B. Davis - Jewish General Hospital"]